Onchocerciasis Clinical Trial
Official title:
Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
This study will investigate the safety and effectiveness of combination regimens in persons with onchocerciasis when it is administered after pre-treatment with ivermectin to clear or greatly reduce microfilariae from the skin and eyes.
The open label, randomized clinical trial studies the safety and efficacy of combination regimens for the treatment of onchocerciasis. Around 300 participants from Bong Mines, Liberia will be randomly assigned to one of four treatment groups after receiving Ivermectin pre-treatment: Ivermectin plus Albendazole (IA0, Ivermectin plus DEC plus Albendazole (IDA), Moxidectin plus albendazole (MoxA), or Moxidectin plus DEC plus Albendazole (MoxDA). Participants will be treated at baseline and 6 months after initial treatment. Safety will be measured through extensive adverse event monitoring from baseline to 6 months. Efficacy of the treatment will be measured at 24 months after the initial treatment by the proportion of all adult female worms that are fertile in the Onchocerca nodules and the percentage of participants without microfilaremia at 6, 18, and 24 months after the first treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00300768 -
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
|
Phase 2 | |
| Not yet recruiting |
NCT04035174 -
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
|
N/A | |
| Recruiting |
NCT03653975 -
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
|
||
| Completed |
NCT03052998 -
Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
|
Phase 4 | |
| Recruiting |
NCT04311671 -
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
|
Phase 3 | |
| Active, not recruiting |
NCT03876262 -
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
|
Phase 3 | |
| Terminated |
NCT04913610 -
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
|
Phase 2 | |
| Completed |
NCT03962062 -
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
|
Phase 1 | |
| Completed |
NCT01905436 -
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
|
||
| Recruiting |
NCT00001230 -
Host Response to Infection and Treatment in Filarial Diseases
|
||
| Completed |
NCT05750043 -
Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan
|
||
| Completed |
NCT05749653 -
Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
|
N/A | |
| Completed |
NCT02078024 -
Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana
|
Phase 3 | |
| Completed |
NCT00127504 -
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
|
Phase 2 | |
| Completed |
NCT03131401 -
Prevalence of LF Infection in Districts Not Included in LF Control Activities
|
||
| Completed |
NCT02032043 -
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
|
||
| Completed |
NCT04188301 -
Safety and Efficacy of IDA for Onchocerciasis
|
Phase 2 | |
| Terminated |
NCT05084560 -
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
|
Phase 1 | |
| Completed |
NCT03517462 -
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
|
N/A | |
| Active, not recruiting |
NCT05180461 -
Emodepside Phase II Trial for Treatment of Onchocerciasis
|
Phase 2 |